Can Pfizer, Sangamo energise haemophilia A gene therapy?

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow.

Sangamo sheds staff once again in another retreat

Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused

Double blow for Sangamo as Novartis, Biogen exit deals

The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.

4DMT's Fabry gene therapy on hold, but 'remains active'

4D Molecular Therapeutics (4DMT) has said a trial of its gene therapy for Fabry disease has been placed on a clinical hold by the FDA, a few weeks after it reported three

Pfizer, Sangamo resume haemophilia gene therapy trial

Pfizer and Sangamo have restarted recruitment of patients into their registration trial for haemophilia A gene therapy giroctocogene fitelparvovec, after the FDA lifted a clinical hold on t

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...